Farago AF, Drapkin BJ, de Ramos J, Galmarini CM, Nunez R, Kahatt C, Paz-Arez L. ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/ vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol. 2019;15(3):231-9. https://doi.org/10.2217/fon-2018-0597

Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. Br J Cancer. 2019;120(3):279-85. https://doi.org/10.1038/s41416-018-0349-6

Xu Y, Wang H, Zhou S, Yu M, Wang X, Fu K, Qian Z, Zhang H, Qiu L, Liu X, Wang P. Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. Leuk Lymphoma. 2013;54(7):1396-404. https://doi.org/10.3109/10428194.2012.743657

Lee Ching C, Kenyon L, Berk M, Park C. Rheumatoid meningitis sine arthritis. J Neuroimmunol. 2019;328:73-5. https://doi.org/10.1016/j.jneuroim.2018.12.001

Cooray S, Zhang H, Breen R, Carr-White G, Howard R, Cuadrado M, D'Cruz D, Sanna G. Cerebral tuberculosis in a patient with systemic lupus erythematosus following cyclophosphamide treatment: a case report. Lupus. 2018;27(4):670-5. https://doi.org/10.1177/0961203317722849

Yu Q, Nie SP, Wang JQ, Huang DF, Li WJ, Xie MY. Molecular mechanism underlying chemoprotective effects of Ganoderma atrum polysaccharide in cyclophosphamide-induced immunosuppressed mice. J Funct Foods. 2015;15:52-60. https://doi.org/10.1016/j.jff.2015.03.015

Becker JC, Schrama D. The Dark Side of Cyclophosphamide: Cyclophosphamide-Mediated Ablation of Regulatory T Cells. J Invest Dermatol. 2013;133:1462-5. https://doi.org/10.1038/jid.2013.67

Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, Beckhove P, Schuetz F. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother. 2012;61(3):353-62. https://doi.org/10.1007/s00262-011-1106-3

Wlodarczyk M, Ograczyk E, Kowalewicz-Kulbat M, Druszczyńska M, Rudnicka W, Fol1 M. Effect of Cyclophosphamide Treatment on Central and Effector Memory T Cells in Mice. Int J Toxicol. 2018;37(5):373-82. https://doi.org/10.1177/1091581818780128

Huyan X, Lin Y, Gao T, Chen RY, Fan YM. Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. Int Immunopharmacol. 2011;11(9):1293-7. https://doi.org/10.1016/j.intimp.2011.04.011

Wójcik R, Dabkowska A. The effect of cyclophosphamide on the selected parameters of immunity in rats. Cent Eur J Immunol. 2010;35(1):1-9.

Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336-44. https://doi.org/10.1002/eji.200324181

Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother. 2002;25:207-17. https://doi.org/10.1097/00002371-200205000-00003

Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, Nagayama Y, Eguchi K. Different mechanisms for anti-tumor effects of low-and high-dose cyclophosphamide. Oncol Rep. 2006;16(1):141-6. https://doi.org/10.3892/or.16.1.141

Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 2010;70(12):4850-8. https://doi.org/10.1158/0008-5472.CAN-10-0283

Zhang WN, Gong LL, Liu Y, Zhou ZB, Wan CX, Xu JJ, Wu QX, Chen L, Lu YM, Chen Y. Immunoenhancement effect of crude polysaccharides of Helvella leucopus on cyclophosphamide-induced immunosuppressive mice. J Funct Foods. 2020;69:103942. https://doi.org/10.1016/j.jff.2020.103942

Kim HI, Kim DS, Jung Y, Sung NY, Kim M, Han IJ, Nho EY, Hong JH, Lee JK, Boo M, Kim HL, Baik S, Jung KO, Lee S, Kim CS, Park J. Immune-Enhancing Effect of Sargassum horneri on Cyclophosphamide-Induced Immunosuppression in BALB/c Mice and Primary Cultured Splenocytes. Molecules. 2022;27:8253. https://doi.org/10.3390/molecules27238253

Zdravkovic N, Shahin A, Arsenijevic N, Lukic ML, Mensah-Brown EP. Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin. Mol Immunol. 2009;47(1):28-36. https://doi.org/10.1016/j.molimm.2008.12.023

Brode S, Raine T, Zaccone P, Cooke A. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J Immunol. 2006;177(10):6603-12. https://doi.org/10.4049/jimmunol.177.10.6603

Kiesel U, Greulich B, Moumé CM, Kolb H. Induction of experimental autoimmune diabetes by low-dose streptozotocin treatment in genetically resistant mice. Immunol Lett. 1981;3(4):227-30. https://doi.org/10.1016/0165-2478(81)90079-1

Kaur S, Tan WL, Soo C, Cheung CC, Stewart J, Reddy S. An immunohistochemical study on the distribution and frequency of T regulatory cells in pancreatic islets of NOD mice during various stages of spontaneous and cyclophosphamide-accelerated diabetes. Pancreas. 2010;39(7):1024-33. https://doi.org/10.1097/MPA.0b013e3181da9037

Heylmann D, Bauer M, Becker H, van Gool S, Bacher N, Steinbrink K, Kaina B. Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response. PLoS One. 2013;8(12):e83384. https://doi.org/10.1371/journal.pone.0083384

Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002;62(10): 2731-5.

Feng L, Huang Q, Huang Z, Li H, Qi X, Wang Y, Liu Z, Liu X, Lu L. Optimized animal model of cyclophosphamide-induced bone marrow suppression. Basic Clin Pharmacol Toxicol. 2016;119(5):428-35. https://doi.org/10.1111/bcpt.12600

Hou F, Yang H, Yu T, Chen W. The immunosuppressive effects of 10 mg/kg cyclophosphamide in Wistar rats. Environ Toxicol Pharmacol. 2007;24(1):30-6. https://doi.org/10.1016/j.etap.2007.01.004

Gonzalez EJ, Peterson A, Malley S, Daniel M, Lambert D, Kosofsky M, Vizzard MA. The effects of tempol on cyclophosphamide-induced oxidative stress in rat micturition reflexes. Sci World J. 2015;2015:545048. https://doi.org/10.1155/2015/545048

Li P, Chen F, Zheng J, Yang Y, Li Y, Wang Y, Chen X. Cyclophosphamide abrogates the expansion of CD4+Foxp3+ regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas. Cancer Biol Med. 2021;18(4):1010-20. https://doi.org/10.20892/j.issn.2095-3941.2021.0027

Zhong H, Lai Y, Zhang R, Daoud A, Feng Q, Zhou J, Shang J. Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway. Int J Mol Sci. 2020;21(3):957. https://doi.org/10.3390/ijms21030957

Noh EM, Kim JM, Lee HY, Song HK, Joung SO, Yang HJ, Kim MJ, Kim KS, Lee YR. Immuno-enhancement effects of Platycodon grandiflorum extracts in splenocytes and a cyclophosphamide-induced immunosuppressed rat model. BMC Complement Altern Med. 2019;19(1):322. https://doi.org/10.1186/s12906-019-2724-0

Salem ML, Al-Khami AA, El-Nagaar SA, Zidan AA, Al-Sharkawi IM, Marcela Díaz-Montero C, Cole DJ. Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. Cell Immunol. 2012;276(1-2):67-74. https://doi.org/10.1016/j.cellimm.2012.03.010

Huang R, Zhang J, Liu Y, Hao Y, Yang C, Wu K, Cao S, Wu C. Immunomodulatory effects of polysaccharopeptide in immunosuppressed mice induced by cyclophosphamide. Mol Med Rep. 2013;8(2):669-75. https://doi.org/10.3892/mmr.2013.1542

Zhang Z, Pan T, Liu C, Shan X, Xu Z, Hong H, Lin H, Chen J, Sun H. Cyclophosphamide induced physiological and biochemical changes in mice with an emphasis on sensitivity analysis. Ecotoxicol Environ Saf. 2021;211:111889. https://doi.org/10.1016/j.ecoenv.2020.111889

Yang H, Choi K, Kim KJ, Park SY, Jeon JY, Kim BG, Kim JY. Immunoenhancing Effects of Euglena gracilis on a Cyclophosphamide-Induced Immunosuppressive Mouse Model. J Microbiol Biotechnol. 2022;32(2):228-37. https://doi.org/10.4014/jmb.2112.12035

Ikezawa Y, Nakazawa M, Tamura C, Takahashi K, Minami M, Ikezawa Z. Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. J Dermatol Sci. 2005;39(2):105-12. https://doi.org/10.1016/j.jdermsci.2005.02.002

Salem ML, Kadima AN, El-Naggar SA, Rubinstein MP, Chen Y, Gillanders WE, Cole DJ. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007;30(1):40-53. https://doi.org/10.1097/01.cji.0000211311.28739.e3

Shurlygina AV, Mel'nikova EV, Trufakin VA. Chronodependent effect of interleukin-2 on mouse spleen cells in the model of cyclophosphamide immunosuppression. Bull Exp Biol Med. 2015;158(4):471-4. https://doi.org/10.1007/s10517-015-2787-y

Zdravkovic N, Pavlovic S, Zdravkovic V, Pejnovic N, Arsenijevic N, Lukic ML. ST2 gene-deletion reveals a role of Foxp3+ regulatory T cells in diabetes modulation in BALB/c mice. Transl Res. 2013;161(2):118-29. https://doi.org/10.1016/j.trsl.2012.10.005